Показаны сообщения с ярлыком estimate. Показать все сообщения
Показаны сообщения с ярлыком estimate. Показать все сообщения

вторник, 11 октября 2011 г.

HIV/AIDS prevention initiative averts 100,000 infections in India

Evaluation study of Avahan prevention program shows promising effects for future efforts and highlights the need for building program evaluations into public health interventions. October 10, 2011 – An ambitious, large-scale HIV/AIDS public health program prevented an estimated 100,000 new infections over five years in the parts of India hardest hit by the AIDS epidemic, indicating that HIV prevention programs that target high-risk groups can reduce HIV rates in the broader population. This is according to a new analysis by the Public Health Foundation of India (PHFI) and the Institute for Health Metrics and Evaluation (IHME) at the University of Washington in collaboration with colleagues at the Ministry of Health and Family Welfare in India.
In three of six states where the Avahan program was implemented, the study found significant reductions in HIV infections, but in the smaller northeastern states, the program appeared to have little or no significant impact. The researchers say the lack of success in some parts of India shows the need to carefully plan programs and to include an ongoing evaluation of the program’s effectiveness from the beginning. The study, “Assessment of population-level effect of Avahan, an HIV-prevention initiative in India,” is published in The Lancet. “The impact of HIV prevention on high-risk groups such as sex workers and injection drug users has been shown before, but this study shows the broad impact that HIV prevention can have on overall incidence of HIV,” says Dr. Marie Ng, the study’s lead author, who is a former IHME Post-Graduate Fellow and now an Assistant Professor at the University of Hong Kong. “Even though it will take several more years to truly assess the effectiveness of Avahan, we can say that this initial assessment is encouraging.” India has an estimated 2.4 million people with HIV, making it one of the largest infected populations in the world. Launched in 2003, Avahan targeted the states with the highest HIV rates at the time: four large states in south India — Andhra Pradesh, Karnataka, Maharashtra, and Tamil Nadu—and two small states in the northeast—Manipur and Nagaland. Together, the states had a total population of 300 million.
Avahan focused on high-risk groups, such as sex workers and their clients, men who have sex with men, and injecting drug users. The program included peer outreach for safe-sex counseling, treatment for sexually transmitted infections, distribution of free condoms, needle and syringe exchanges, and community advocacy activities. Previous research showed that Avahan has successfully scaled up these interventions. Research also found a subsequent decline in HIV rates among sex workers in some parts of Karnataka, but no previous study has measured the effect of the program on the general population.
This study shows that Avahan had a significant beneficial effect on HIV prevalence in Andhra Pradesh, Karnataka, and Maharashtra, borderline significant effect in Tamil Nadu, and no significant effect in Manipur and Nagaland. Because of Avahan, between 2003 and 2008 the HIV prevalence in the general population fell at the highest by 12.7% in Karnataka and at the lowest by 2.4% in Maharashtra.
The study estimates the cost for each infection averted to be about $2,500, making the program cost-effective compared to the amount of care required to treat a patient with AIDS over his or her lifetime. The first phase of Avahan, from 2003 to 2008, was funded by $258 million from the Bill & Melinda Gates Foundation, which also provides funding to PHFI and IHME. The foundation has continued to fund Avahan while it is being transitioned to control by the Indian government.
“There has been a lull in HIV prevention funding in recent years, with funding shifting to treatment, largely because of increasing evidence on the success of antiretroviral therapies,” says Dr. Lalit Dandona, the study’s senior author, Distinguished Research Professor at PHFI in New Delhi, and Professor of Global Health at IHME. “This study suggests that prevention programs that invest in good planning and management can be effective on a large scale and therefore deserve a balanced infusion of funds.”
Under ideal conditions, a prospective evaluation of the impact of Avahan in the general population would have been rolled out simultaneously with the program, the authors note. This would have allowed researchers to more effectively compare populations that were not covered by Avahan efforts to populations that were covered.
“It’s always hard to thoroughly evaluate a program after the fact,” says Dr. Emmanuela Gakidou, Associate Professor of Global Health at IHME and one of the paper’s co-authors. “Our hope is that as the program is expanded or applied in other countries, the evaluation piece will be built into it from day one. If we don’t know how exactly these programs are working, we won’t know how to maximize their impact.”
The Public Health Foundation of India (PHFI) was launched by the Prime Minister of India in 2006 as a response to redress the limited institutional capacity in India to strengthen training, research, and policy development in public health. It is a public-private partnership that has collaboratively evolved through consultations with multiple constituencies including Indian and international academia, state and central governments, multilateral and bilateral agencies, and civil society groups. PHFI is establishing a network of Indian Institutes of Public Health across the country. The governing board of PHFI includes leading experts in public health and policy internationally and from India.
The Institute for Health Metrics and Evaluation (IHME) is an independent global health research center at the University of Washington that provides rigorous and comparable measurement of the world's most important health problems and evaluates the strategies used to address them. IHME makes this information freely available so that policymakers have the evidence they need to make informed decisions about how to allocate resources to best improve population health.
Media contacts PHFI in New Delhi: Ms. Vijayluxmi Bose Tel: +91 11 4604 6000; Mobile: +91 98114 15443 vbose@phfi.org IHME in Seattle: Mr. William Heisel Tel: +1-206-897-2886; Mobile: +1-206-612-0739 wheisel@uw.edu

среда, 5 октября 2011 г.

HIV: New facts and stunning data visuals

среда, 18 ноября 2009 г.

usuful

One of K populations is chosen according to some given selection procedure. Population i has the parameter θ i associated with it. The θ value for the chosen population is to be estimated using only the data on which the selection was made. Some general results relating to Bayes and minimax rules as well as the minimax value are obtained. Applications of these results to particular problems are given.

Evaluating the Chosen Population: A Bayes and Minimax Approach, by Harold Sackrowitz and Ester Samuel-Cahn © 1986

понедельник, 16 ноября 2009 г.

latest lancet paper

Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: a systematic review

We systematically reviewed the accuracy of serological tests for recent infections with HIV that have become widely used for measuring population patterns incidence of HIV. Across 13 different assays, sensitivity to detect recent infections ranged from 42—100% (median 89%). Specificity for detecting established infections was between 49·5% and 100% (median 86·8%) and was higher for infections of durations longer than 1 year (median 98%, range 31·5—100·0). For four different assays, comparisons were made between assay-derived population incidence estimates and a reference incidence estimate. The median percentage difference between the assay-derived incidence and reference incidence was 26·0%. Serological assays have reasonable sensitivity for the detection of recent infection with HIV, but are vulnerable to misclassifying established infections as recent—potentially leading to biases in incidence estimates. This conclusion is highly qualified by the apparent absence of a standardised approach to assay evaluation. There is an urgent need for an internationally agreed framework for evaluating and comparing these tests.

понедельник, 3 ноября 2008 г.

Evaluating HIV Estimates from National Population-Based Surveys

Evaluating HIV Estimates from National Population-Based Surveys for Bias Resulting from Non-Response (English)

Reliable data on HIV prevalence are essential for assessing the scope of and effectively managing the response to the epidemic. Antenatal clinic-based surveillance is commonly used to monitor trends in HIV in developing countries that have generalized epidemics. Recently, HIV seroprevalence data have been also collected in national population-based surveys, such as the Demographic and Health Surveys (DHS) and AIDS Indicators Surveys (AIS). Such surveys enable direct estimation of population HIV prevalence. A major challenge for population-based surveys is bias resulting from non-response, both from refusal and absence. In this study, we evaluate national HIV prevalence estimates from DHS and AIS surveys for bias resulting from non-response in the surveys. Data are from 17 recent national DHS and AIS surveys with HIV testing – Burkina Faso, Cambodia, Cameroon, Cote d’Ivoire, the Dominican Republic, Ethiopia, Ghana, India, Kenya, Lesotho, Malawi, Mali, Rwanda, Tanzania, Uganda, Zambia, and Zimbabwe – conducted during 2001 and 2006. Blood samples were collected and tested for HIV using standard laboratory and quality-control procedures. In the first three surveys, in Mali, Zambia, and the Dominican Republic, HIV status could not be linked to the characteristics and behaviors of the survey respondents. For each of the other 14 countries with HIV serostatus data linked to individual characteristics and behaviors, we predict HIV prevalence among non-responding adults on the basis of multivariate statistical models of HIV for those who were interviewed and tested, using a common set of predictor variables. Predictions are made separately for two groups of non-respondents: not interviewed/not tested and interviewed/not tested. Adjusted HIV prevalence is calculated as a weighted average of observed prevalence in the interviewed/tested group and predicted prevalence in the two non-tested groups. Predictions are made separately for adult males and females. In the 14 countries with linked data, the HIV testing rate varied from a low of 63 percent among men in Malawi and Zimbabwe to a high of 97 percent among women in Rwanda. Non-response rate was higher among urban, more educated, and wealthier men and women but had no clear association with various risk and protective behavioral factors. Non-tested men had significantly higher predicted HIV prevalence than those tested in 8 of the 14 countries, and non-tested women had significantly higher predicted prevalence than those tested in 7 of the 14 countries. Although non-tested men and women tend to have higher predicted HIV prevalence than those tested, the overall effect of non-response bias on observed prevalence estimates was small and not significant in all countries. In the 14 countries, HIV prevalence estimates adjusted for non-response bias were on average only 3 percent and 2 percent higher than the observed, non-adjusted estimates for men and women, respectively. The study finds that non-response for HIV testing tends to have small, non-significant effects on national HIV seroprevalence estimates obtained from national household surveys. National population-based surveys are an important source of reliable data on HIV prevalence that can enhance surveillance-based estimates in generalized epidemics.

full text in pdf about 3 mb

четверг, 17 апреля 2008 г.

ifp

Estimating incidence from prevalence in generalised HIV epidemics:
Methods and validation
PLoS Medicine. 2008 Apr;5(4):e80.
Hallett TB | Zaba B | Todd J | Lopman B | Mwita W
HIV surveillance of generalised epidemics in Africa primarily relies on prevalence at antenatal clinics, but estimates of incidence in the general population would be more useful. Repeated cross-sectional measures of HIV prevalence are now becoming available for general populations in many countries, and we aim to develop and validate methods that use these data to estimate HIV incidence. Two methods were developed that decompose observed changes in prevalence between two serosurveys into the contributions of new infections and mortality. Method 1 uses cohort mortality rates, and method 2 uses information on survival after infection. The performance of these two methods was assessed using simulated data from a mathematical model and actual data from three community-based cohort studies in Africa. Comparison with simulated data indicated that these methods can accurately estimates incidence rates and changes in incidence in a variety of epidemic conditions. Method 1 is simple to implement but relies on locally appropriate mortality data, whilst method 2 can make use of the same survival distribution in a wide range of scenarios. The estimates from both methods are within the 95% confidence intervals of almost all actual measurements of HIV incidence in adults and young people, and the patterns of incidence over age are correctly captured. It is possible to estimate incidence from cross-sectional prevalence data with sufficient accuracy to monitor the HIV epidemic. Although these methods will theoretically work in any context, we have able to test them only in southern and eastern Africa, where HIV epidemics are mature and generalised. The choice of method will depend on the local availability of HIV mortality data.